Debt, convertible securities and royalty financing let biotech companies raise capital without relying entirely on new common shares. Each creates a different claim on future value. A loan requires interest and repayment, a convertible note can become equity, and a royalty agreement transfers part of a product’s future receipts. The immediate benefit is cash. The investment question is what shareholders give up to obtain it, and whether the financing carries the business far enough to justify that cost.
These arrangements belong within biotech financial analysis and valuation, rather than being treated as separate balance sheet details. A company can report a large cash balance while facing restrictive covenants, conditional funding or a substantial repayment before its next reliable source of income. Assess the proceeds available today, the obligations created, and the cash shareholders retain under different development and sales outcomes.
How the Main Financing Structures Compare
The distinction between equity dilution and financing cost matters. A transaction can preserve the share count while reducing the economic value attached to each share. Debt interest consumes cash that could fund research. Royalty payments reduce retained product receipts. Convertible securities can postpone dilution rather than prevent it. Compare these alternatives with an ordinary share issue using the same operating assumptions, including the possibility that another financing becomes necessary later. The separate analysis of share dilution and equity offerings covers the mechanics of issuing common stock.
| Structure | What the capital provider receives | Main cash obligation | What to examine |
|---|---|---|---|
| Term debt | Interest, repayment and any contractual fees | Scheduled interest and principal | Collateral, covenants, maturity and repayment capacity |
| Convertible debt | Interest and a contractual conversion right | Interest, plus repayment or conversion settlement | Conversion formula, settlement terms and potential dilution |
| Royalty financing | A defined share of product sales or royalty receipts | Payments determined by the agreement | Payment base, duration, caps and minimum return provisions |
| Development funding | Negotiated success payments, royalties or other returns | Payments tied to agreed development outcomes | Who bears failure risk and what success triggers |
Debt Financing: Repayment Capacity Comes First
Debt advances cash against a future repayment obligation. For a biotech investor, the central question is what will produce that repayment: existing product receipts, a partner payment, an asset sale or another capital raise. These are not interchangeable. A company with established cash generation has a different repayment profile from one whose funding plan depends on a successful trial. Evaluate the borrowing against the company’s development stage and commercial maturity, but do not let a stage label replace a cash forecast. An approved product can still consume cash during its launch.
Look Beyond the Stated Interest Rate
The stated rate is only part of the borrowing cost. Review issuance discounts, arrangement fees, exit payments and any warrants issued to the lender. A floating interest rate introduces another variable: cash interest changes when the contractual reference rate changes, subject to any floor or cap. Payment in kind interest, often called PIK, adds interest to the outstanding debt instead of paying it immediately. That preserves cash for the moment. It also increases the amount that must eventually be repaid, potentially with further interest charged on the enlarged balance.
Consider a hypothetical three year loan with $100 million of principal, $98 million of net proceeds, annual cash interest of $10 million and a $5 million exit payment. Assuming no early repayment, the company receives $98 million and pays $135 million over the term: $30 million of interest, $100 million of principal and the exit payment. The $37 million difference is the financing cash cost before considering timing or taxes. Calling this simply a “10% loan” misses the upfront deduction and exit payment. Calculate the return using dated cash flows when comparing it with another offer.
Covenants Can Shorten Usable Runway
Covenants are contractual promises that can restrict how the borrower operates or uses its assets. Read the actual agreement for minimum cash requirements, revenue tests, restrictions on further borrowing and conditions governing asset sales or licensing. Also identify which subsidiaries guarantee the debt and which assets secure it. A minimum cash covenant creates a practical funding boundary before the bank balance reaches zero. Model that boundary separately from accounting restrictions on cash; money can remain classified as unrestricted yet still be needed to maintain covenant compliance.
BridgeBio provides a historical illustration. Its September 30, 2024 financing disclosures reported a minimum unrestricted qualified cash balance of $78 million. They also reported $434 million of net proceeds from an initial $450 million term loan, after debt discount and issuance costs. Those figures show why principal borrowed, cash received and cash available to spend are different measures. The details appear in BridgeBio’s September 2024 debt financing note. For runway analysis, reserve the applicable covenant buffer before estimating how long spending can continue.
A useful cash burn and runway model therefore tracks more than operating expenditure. Add interest, required principal repayments and any contractual cash reserve. Keep undrawn facilities separate until their availability conditions are met. An agreement described as “up to $300 million” does not establish that the full amount is available on demand. Funding may require approval, a sales threshold, further lender consent or another event. Conditional capital should not fund an unconditional spending plan.
Match Maturity to the Financing Calendar
A maturity date after a planned trial result can still leave little room for error. Enrollment may take longer, a regulator may request more evidence, or a launch may require more working capital than expected. Map debt payments against clinical, regulatory and partnership milestones, allowing time to arrange funding after the event. Inspect provisions that can bring repayment forward, including earlier maturity triggers linked to other debt. A refinancing assumption deserves its own downside case; it is not cash already committed to the business.
Convertible Securities: Model Both Repayment and Dilution
A convertible note combines borrowing with a contractual right to convert into equity or receive a settlement linked to equity value. Start with the principal amount, interest rate and maturity, then examine the conversion terms. Who can elect conversion? When does that right become available? Can the company settle in cash, shares or a combination? These questions determine whether a successful share price outcome creates dilution, a cash requirement or both. A note does not cease to be a repayment concern simply because its initial conversion price sits above the current share price.
Suppose a hypothetical company issues $200 million of notes with a fixed conversion price of $25. Full conversion into shares would create 8 million shares, before contractual adjustments. If 40 million shares were previously outstanding, the resulting count would be 48 million. Existing shareholders would retain 83.3% of the enlarged share base. This is an ownership calculation, not a valuation forecast: the company also received financing, and conversion would remove the corresponding debt obligation. If the shares instead trade well below the conversion price near maturity, repayment may remain the more pressing issue.
Fixed Conversion Prices Differ From Resetting Formulas
Do not apply the fixed price calculation to a security whose conversion formula changes with the market price. A formula that converts at a discount to a falling share price can require progressively more shares for the same principal amount. A contractual floor may constrain that exposure; its wording matters. The SEC’s explanation of convertible securities and conversion risks distinguishes conventional fixed conversion formulas from market price based arrangements and describes the dilution risks of the latter. Inspect adjustment provisions rather than assuming every convertible behaves like a standard institutional note.
Convertible preferred shares require a separate reading. They may carry dividend rights, liquidation preferences or redemption provisions rather than the same obligations as a note. The label “convertible” identifies a conversion feature, not the full economic bargain. For either structure, model the rights that survive if conversion never occurs. Also inspect what happens on an acquisition or other defined corporate event. A financing that appears manageable during ordinary operations can impose a different cash settlement or conversion outcome when ownership changes.
Capped Calls Have a Cost and a Ceiling
A capped call is a separate option arrangement that can offset part of a convertible note’s dilution or cash settlement exposure over an agreed price range. Its protection stops at a contractual cap, and buying it uses proceeds that would otherwise remain available to the company. Keep the option’s economics separate from the noteholder’s conversion rights. The capped call does not remove the note’s maturity obligation, nor should its cap price be substituted for the note’s conversion price when calculating the holder’s entitlement.
Alnylam’s September 2022 financing illustrates the distinction. The company issued $1.04 billion of 1% convertible senior notes due in 2027 and paid $118.6 million, including expenses, for associated capped calls. The notes initially converted at approximately $286.20 per share; the capped calls had an initial cap price of $424. These were different contractual reference points. Alnylam’s 2022 annual report sets out the terms and the protection ceiling. Assessing the financing requires the option cost as well as the low cash coupon.
Royalty Financing: Cash Today for Future Product Economics
Royalty financing exchanges an upfront payment, or staged funding, for rights to a defined stream of future receipts. Two structures deserve separation. A company can sell part of an existing royalty entitlement arising from a licensing agreement. Alternatively, it can promise a percentage of sales from a product it commercializes itself. The first transfers part of an incoming payment stream; the second creates an outgoing claim against product receipts. Neither necessarily transfers operating control of the medicine. Their economics depend on the rights sold, which may differ from those in an ordinary biotech licensing transaction.
Establish What the Percentage Applies To
A royalty rate means little without its denominator. Five percent of product net sales differs sharply from 50% of a royalty that itself equals 10% of those sales. Under the latter simplified assumptions, the buyer’s effective participation is 5% of product net sales, before any contractual adjustments. Check covered products, territories and permitted deductions, along with whether milestones are included. Confirm who collects the money and how the seller receives its retained portion. The phrase “royalty interest” alone does not establish any of those terms.
BridgeBio’s January 18, 2024 financing announcement described $500 million payable upon FDA approval of acoramidis, subject to conditions, in exchange for a 5% royalty on worldwide net sales. Total royalty payments were capped at 1.9 times invested capital. The package also included debt refinancing and a further credit tranche requiring mutual consent. BridgeBio’s original royalty and credit financing announcement shows why a headline funding total needs to be separated into its components. At announcement, approval dependent royalty proceeds were not equivalent to cash funded at the debt closing.
Read the Cap, Duration and Downside Provisions Together
A payment cap states a maximum under the relevant terms; it does not, by itself, establish a guaranteed payment. Distinguish a capped participation in actual sales from an obligation to deliver a minimum return by a deadline. Search for rate increases, minimum payment commitments, repurchase rights and termination payments. Also establish when the interest expires. A fixed duration, a cumulative payment threshold and an interest lasting through the product’s commercial life create different outcomes. The duration should be evaluated against patent protection and regulatory exclusivity, without assuming those periods exactly match the royalty term.
Consider a hypothetical $100 million advance in exchange for 5% of annual net sales, capped at $200 million of cumulative payments. At constant annual sales of $400 million, payments would be $20 million a year and reach the cap in ten years. At $1 billion of annual sales, payments would be $50 million a year and reach it in four years. This simplified example ignores sales ramps, payment lags and other terms. It demonstrates why a 2 times payment cap is not an annual interest rate: receiving the same total sooner produces a higher annualized return for the capital provider.
Sales linked payments can provide flexibility when sales disappoint, provided the agreement does not impose compensating obligations. Strong sales, meanwhile, can make the financing expensive relative to an uncapped success scenario retained entirely by shareholders. Forecast the payment stream alongside the product’s own economics. Use realized net prices, not an assumed list price, and account for the effects of reimbursement and market access. A royalty on sales can remain payable while manufacturing, selling and development costs leave the company with little operating cash.
How Financing Changes Biotech Valuation
Accounting Labels Do Not Replace Contract Analysis
A royalty transaction can appear as a liability rather than an outright disposal of future revenue. Alnylam’s 2024 annual report provides a concrete example: it accounted for its sale of future inclisiran royalties as debt financing because of its continuing involvement and repayment obligation. Interest expense reflected estimates of future payments, with adjustments as expectations changed. The treatment is set out in Alnylam’s 2024 royalty financing accounting disclosures. That accounting does not establish a universal rule for every royalty deal. Read the transaction’s terms and the company’s explanation of its treatment.
For valuation, distinguish contractual principal, accounting carrying value and the amount needed to settle an obligation. They can differ. Unamortized fees can reduce a debt’s reported carrying value without reducing principal owed. A royalty liability can reflect estimated future payments rather than a conventional fixed principal balance. These differences matter when moving from operating asset value to common equity value. A basic enterprise value calculation is a starting point, but the financing agreements determine which adjustments belong in the shareholder valuation.
Avoid Deducting the Same Obligation Twice
Choose a consistent treatment for royalty financing. One approach values product cash flows before the sold royalty and separately deducts the present value of the buyer’s claim. Another values only the company’s retained cash flows. Under the second approach, subtracting the full corresponding royalty obligation again would count the same economic burden twice. Apply the same discipline to risk adjusted pipeline valuation: funding proceeds, development spending and financing payments must each enter the model once. A liability’s accounting carrying amount need not equal the appropriate economic adjustment.
Convertible notes also require internally consistent scenarios. In a repayment case, retain the debt claim and use the relevant share count. In an equity conversion case, remove the converted principal and add the shares issued under the settlement terms. Do not remove the debt while leaving the share count unchanged unless the modeled settlement genuinely supports that result. Test cash settlement separately where permitted. Use valuation sensitivity analysis to show how financing outcomes change with launch timing, sales and the need for further capital, rather than presenting one diluted share count as inevitable.
Stress Testing the Funding Plan
Build a quarterly cash schedule before deciding whether a financing solves the company’s funding problem. Consider a hypothetical biotech with $150 million of opening cash, $120 million of net new loan proceeds and a $30 million minimum cash requirement. It has $240 million of spending capacity above that boundary. Assume operating cash use, excluding financing costs, is $20 million per quarter and cash interest is $3 million. Before principal repayments or other cash movements, that capacity covers about 10.4 quarters. Dividing total cash by operating burn alone would produce a misleading 13.5 quarters.
| Stress | Model adjustment | Question to answer |
|---|---|---|
| Trial result delayed | Extend development spending and defer associated funding | Does cash remain above the covenant boundary? |
| Slower launch | Reduce collections while retaining committed launch costs | Can the company service debt during the sales ramp? |
| Conditional tranche unavailable | Remove the undrawn proceeds | Which spending must stop or find replacement funding? |
| No attractive refinancing | Require repayment under existing terms | Is an equity issue or asset sale necessary? |
Separate operating progress from financing availability. A successful approval does not guarantee rapid collections, and reported revenue does not necessarily arrive as cash in the same quarter. Inventory and receivables can absorb funding during a drug launch and adoption period. For a royalty arrangement, weaker sales may lower payments to the funder while also reducing the company’s retained cash. Model both effects. Treat reduced royalty payments as partial relief, not as protection against the entire commercial shortfall.
What to Extract From the Filings
Use the announcement to identify the transaction, then move to the agreement, subsequent amendments and financial statement notes. The original terms may no longer describe the outstanding obligation. Build a dated financing worksheet and reconcile it with the cash flow statement and balance sheet. A structured approach to biotech filings and research sources helps separate management’s funding description from the contractual conditions. Keep the worksheet concise enough to update after each quarterly report.
- Available proceeds: cash received, fees deducted, restricted amounts and conditions on future funding.
- Payment schedule: cash interest, principal, royalties, exit fees and success payments.
- Control provisions: collateral, guarantees, covenants, default triggers and required consents.
- Equity exposure: conversion formulas, warrants, settlement choices and capped call terms.
- Corporate events: acquisition payments, mandatory prepayments and termination provisions.
Record the first date at which the company needs a decision, not simply the final maturity date. That may be a covenant test, the deadline for accessing a tranche or the point at which management must begin raising replacement capital. Update that date when spending, trial timing or sales expectations change. For each funding source, identify the action required if it fails to arrive. The worksheet should make that dependency visible before the remaining cash forces the decision.